FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens
- FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens Sanofi’s Monopoly Federal Trade Commission News
- Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics GlobeNewswire
- Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound STAT
- After feds steps in, French drugmaker pulls out of $750M deal with Peninsula biotech – San Francisco Business Times The Business Journals
- Sanofi scraps Maze deal after FTC throws up antitrust obstacles FierceBiotech
Read More: FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens